Wireless Implant Restored Normal Glucose in Diabetic Mice Within an Hour

A wirelessly powered implant restored elevated blood glucose to the normal range within one hour in obese mice with type 2 diabetes, operating at 0.75 volts and 10 milliamperes. Researchers at ETH Zürich, the University of Lyon, and the University of Basel report the results in Science Advances, positioning the device, called ECHO, as a drug-free route to managing the linked disorders of obesity and T2D, known collectively as diabesity.

The device works by consuming glucose rather than delivering a drug. Its electrode carries platinum-decorated gold nanoclusters embedded in a porous, conductive graphite felt matrix. Under electrical activation, this electrocatalyst converts circulating glucose into gluconate, which the kidneys then excrete.

Lead developer Debasis Maity and colleagues coupled the implant to a continuous glucose monitor through a smartphone. The CGM streamed readings to the phone; the phone sent instructions back to ECHO; the implant switched on only when glucose crossed a predefined threshold. "The CGM system tracked glucose concentrations and transmitted the data to a smartphone, which processed the data and sent instructions back to the ECHO device, which in turn rapidly adjusted glucose concentrations to maintain homeostasis in response—achieving this without hypoglycemic episodes or the need for small-molecule drugs or biopharmaceuticals," the authors wrote.

What did the six-week mouse study show?

Over six weeks of repeated treatments, the mice maintained glucose control, according to the paper. Lowering glucose shifted whole-body metabolism from glucose toward stored fat, producing measurable weight reduction. Triglyceride levels fell, while circulating free fatty acids and ketone bodies rose — a metabolic profile consistent with fat oxidation.

The authors report no detectable hypoglycemic episodes and no adverse effects on physiological function, inflammation, or behavior. That safety record, however, covers one mouse model over six weeks; the paper offers no data on long-term implant durability, catalyst fouling, or scaling the glucose-removal rate to human blood volumes. No funding disclosure or timeline toward clinical testing appears in the announcement.

Why target diabesity without drugs?

Obesity and diabetes reinforce each other through metabolic, hormonal, and inflammatory pathways, the authors note. "Current treatments rely largely on drugs that lower blood glucose or body weight, but these therapies can produce side effects, require lifelong administration, and may lose effectiveness over time," they wrote. Emerging alternatives — engineered therapeutic cells and dual weight-glucose drugs — remain constrained by safety and cost concerns.

The team's proposal is an implant whose dose is set electrically. "A subcutaneous implant containing a solid electrocatalyst that directly removes excess glucose from the bloodstream at an electrically adjustable rate could provide a dose-controllable, drug-free therapeutic alternative," the authors stated. Senior and corresponding author Martin Fussenegger, PhD, professor at ETH Zürich's Department of Biosystems Science and Engineering, leads the Basel-based group behind the work.

Is this a platform or a one-metabolite fix?

The researchers argue the concept extends beyond glucose. "We believe that closed-loop electrocatalytic devices could establish a platform concept for regulating disease-relevant metabolites, offering a potential route toward drug-sparing, dynamically controlled metabolic interventions," they wrote in the paper's summary.

A accompanying perspective from William Bentley, PhD, and Gregory Payne, PhD, of the Fischell Department of Bioengineering at the University of Maryland supports that reading. "Existing bioelectronics devices provide notable access to the nervous and neuromuscular systems … future electronic intervention devices might help to manage diseases other than diabetes, modulate human-microbiome interactions, or maintain redox homeostasis in stress conditions, among many other applications," they wrote.

For R&D managers weighing closed-loop bioelectronics portfolios, the result is a mouse proof-of-concept with concrete electrical specifications and a clean six-week safety profile — not a clinical candidate. Human translation will need to answer whether a glucose-consuming catalyst can match the minute-to-minute dynamics of insulin at human scale.